Clinical Trials
285 trialsNeoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Iovance Biotherapeutics, Inc.
Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC
University of Texas Southwestern Medical Center
Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
Incyte Corporation
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
McGill University Health Centre/Research Institute of the McGill University Health Centre
PIPSeN
Gustave Roussy, Cancer Campus, Grand Paris
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Hoffmann-La Roche
OPTIMUNELUNG
Institut Bergonié
Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
M.D. Anderson Cancer Center
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
Thomas Jefferson University
Tamarack
MacroGenics
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
University of Pittsburgh
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
Dana-Farber Cancer Institute
ATLAS
University Health Network, Toronto
HBI-8000
HUYABIO International, LLC.
BRIDGE
Mario Negri Institute for Pharmacological Research
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Regeneron Pharmaceuticals
Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC
Oncology Institute of Southern Switzerland
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Sotio Biotech Inc.
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
ImmuneSensor Therapeutics Inc.
Geometry-N
Novartis
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
Sanofi
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
Bristol-Myers Squibb
Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
GlaxoSmithKline
Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
Grid Therapeutics
IRRADIATE-Lung
NYU Langone Health
Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
DESTINY-Lung01
Daiichi Sankyo
ESR1814205
Rush University Medical Center
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
ImmunoGenesis
Induction Chemo-Nivo in Unresectable Stage III NSCLC
University of Kentucky
A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer
Faeth Therapeutics
KEYNOTE B36
NovoCure Ltd.
Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC
Yale University
ALERT-lung
ETOP IBCSG Partners Foundation
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
Fundación GECP
Study of INCB086550 in Select Solid Tumors
Incyte Corporation
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Seagen Inc.
Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS
Spanish Lung Cancer Group
Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma
Emory University
--SuPERIOR Trial--
University Health Network, Toronto
IMMUNOSABR2
Maastricht University Medical Center
A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
Tufts Medical Center
Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects
MedPacto, Inc.
A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations
Astellas Pharma Inc
Milademetan in Advanced/Metastatic Solid Tumors
Rain Oncology Inc